Roche’s antibody cocktail launched in India at ₹59,750/dose
PTI
New Delhi |
Updated on
May 24, 2021
Cipla to market drug in country
Drug majors Roche India and Cipla on Monday announced launch of Roche s Antibody Cocktail in India priced at ₹59,750 per dose for the treatment of mild to moderate Covid-19 in patients who are at high risk.
“The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement. Cipla will distribute the product by leveraging its strong distribution strengths across the country, it added.
UPDATED: May 24, 2021 13:51 IST
The drug will be available through leading hospitals and Covid treatment centers. (Photo: PTI/ for Representation)
Drug majors Roche India and Cipla on Monday announced launch of Roche s Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate Covid-19 in patients who are at high risk. The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement.
Roche, Cipla launch antibody cocktail Casirivimab and Imdevimab in India: Know price, function, benefits
The antibody cocktail is targeted at mild-to-moderate coronavirus patients above 12 years of age or older and at least weighing 40 kg. (Photo: India.com)
Updated: May 24, 2021, 05:52 PM IST
Indian Pharma giants Roche India and Cipla limited in a partnership have announced the antibody cocktail Casirivimab and Imdevimab, now available in India.
This intravenous administration of the cocktails (Casirivimab & Imdevimab) 4 syringes (2 of each of 2.5ml) need to be injected simultaneously at 4 points on the abdomen or thigh. One patient requires 1200mg of dosage which is 1200mg will be sold at MRP of Rs 59,750. The multi-dose pack containing 2400mg of the cocktail can treat 2 patients per pack will be sold at the MRP of Rs 1,19,500.
2575
New Delhi, May 24
Drug majors Roche India and Cipla on Monday announced the launch of Roche s Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate COVID-19 in patients who are at high risk. The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement.
Cipla will distribute the product by leveraging its strong distribution strengths across the country, it added.
Rocheâs antibody cocktail to treat COVID-19 now available in India
Rocheâs antibody cocktail to treat COVID-19 now available in India
24 May 2021 | News Cipla to market the drug pan-India
Roche India and Cipla have announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June.
In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients.
Cipla will distribute the product by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and COVID treatment centres.